Lilly Wants Records of People Who Took Weight-Loss Knockoffs
Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their medical records as it continues to build a case against businesses selling the compounded drugs.
Eli Lilly wants records of people who took copies of its weight-loss drug
“I am gobsmacked that Lilly is seeking confidential patient medical records to build a case against the very therapies that are benefiting those patients at a time when Lilly’s own drugs are not available to those patients,” said Scott Brunner, chief executive officer of the Alliance for Pharmacy Compounding, an industry trade group.
Weight loss market: Smaller rivals muscle in on Eli Lilly and Novo Nordisk
As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up to release their own treatments, aiming to challenge the two industry leaders.
Eli Lilly request records of people who took copies of its weight-loss drug
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell the compounded versions has intensified.
Lilly asks people who took compounded tirzepatide for their medical records
Eli Lilly (NYSE:LLY) is taking the unusual step of asking people who took compounded versions of their drug tirzepatide, marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes, for medical records to examine potential safety concerns.
The Price War in Weight-Loss Drugs Is Here
Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...
Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
U.S. weight-loss medicine makers cut prices for insurance inclusion: WSJ
Eli Lilly and Novo Nordisk the pharmaceutical heavyweights selling popular weight-loss injections are each dangling discounts to gain an edge and to ...
This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
New York Post24d
Eli Lilly slashes price of weight-loss drug Zepbound by 50% to sell in smaller doses
Eli Lilly said it has started selling single-dose vials of its uber-popular weight-loss drug Zepbound as demand soars – and the smaller doses cost 50% less than rival drugs. The more ...
The Washington Post20d
Eli Lilly ramps up its fight against imitation weight-loss drugs
Eli Lilly and rival Novo Nordisk have been battling the emerging industry making copies of their top-selling diabetes and weight-loss drugs, a situation without modern precedent. It started in ...
Prediction: This Will be Eli Lilly's Next Big Move.
Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...
USA Today23d
Eli Lilly launches new version of its popular weight loss drug at a discount
Eli Lilly said it has begun selling vials of the smallest, starter dose of its popular weight-loss drug Zepbound in the United States for $399 for a month on its direct-to-consumer website to ...